Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22230009 | 0.80 | PCSK9 (0.42) | CHRNB2CHRNA4PCSK9PPARAAOC3 | |
| SCHEMBL12404673 | 0.80 | PPARA (0.46) | PIK3CDPCSK9PPARAAOC3PTGS2 | |
| SCHEMBL2611132 | 0.79 | NR1H3 (0.45) | MEN1KMT2APPARAAOC3NOTUM | |
| SCHEMBL31642358 | 0.79 | AOC3 (0.42) | CHRNB2CHRNA4PCSK9PPARACYP2A6 | |
| SCHEMBL12331975 | 0.74 | PPARA (0.37) | PCSK9PPARAAOC3 | |
| SCHEMBL2611130 | 0.74 | CHRNB2 (0.42) | CHRNB2CHRNA4PIK3CDMEN1KMT2A | |
| SCHEMBL20031404 | 0.73 | PPARA (0.39) | PCSK9PPARAAOC3 | |
| SCHEMBL15885947 | 0.73 | KEAP1 (0.52) | CHRNB2CHRNA4PIK3CDMEN1KMT2A | |
| SCHEMBL21408699 | 0.73 | PPARA (0.46) | PCSK9PPARAAOC3 | |
| SCHEMBL15885979 | 0.72 | CHRNB2 (0.41) | CHRNB2CHRNA4PIK3CDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849053-B | Spiro compounds | 里科瑞尔姆IP控股有限责任公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200268714-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| US-20200268714-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| EP-3277690-B1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3277690-B1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2018-07-26 | — | — | US | disclosed |
| US-20130261141-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| EP-2630133-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | Bayer Intellectual Property GmbH (DE) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012052412-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2012-04-26 | — | — | WO | disclosed |
| US-8101550-B2 | Anthranilic acid diamide derivative with hetero-aromatic and hetero-cyclic substituents | BAYER CROPSCIENCE AG (DE) | 2012-01-24 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| EP-2260031-A1 | COMPOUNDS THAT ARE ERK INHIBITORS | Schering Corporation (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20100029478-A1 | ANTHRANILIC ACID DIAMIDE DERIVATIVE WITH HETERO-AROMATIC AND HETERO-CYCLIC SUBSTITUENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| WO-2009105500-A1 | COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268714-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | CHRNB2 4815/4885CHRNA4 4844/4885PIK3CD 1620/4885 |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | CHRNB2 4815/4885CHRNA4 4844/4885PIK3CD 1620/4885 |
| US-20100029478-A1 | ANTHRANILIC ACID DIAMIDE DERIVATIVE WITH HETERO-AROMATIC AND HETERO-CYCLIC SUBSTITUENTS | DDT, ANTXR2, QDPR | CHRNB2 2371/4885CHRNA4 1339/4885PIK3CD 1211/4885 |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | CHRNB2 4641/4885CHRNA4 4810/4885PIK3CD 164/4885 |
| US-20130261141-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | DDT, ACHE, PTMS | CHRNB2 1073/4885CHRNA4 1068/4885PIK3CD 1981/4885 |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | CHRNB2 4815/4885CHRNA4 4844/4885PIK3CD 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.